Cardiovascular Disease in the Elderly: Proceedings of the European Society of Cardiology-Cardiovascular Round Table

The growing elderly population worldwide represents a major challenge for caregivers, healthcare providers, and society. Older patients have a higher prevalence of cardiovascular (CV) disease, high rates of CV risk factors, and multiple age-related comorbidities. Although prevention and management strategies have been shown to be effective in older people they continue to be under-used, and under-studied. In addition to hard endpoints, frailty, cognitive impairments, and patients' re-assessment of important outcomes (e.g., quality of life versus longevity) are important aspects for older patients and emphasize the need to include a substantial proportion of older patients in CV clinical trials. To complement the often skewed age distribution in clinical trials, greater emphasis should be placed on real-world studies to assess longer-term outcomes, especially safety and quality of life outcomes. In the complex environment of the older patient, a multidisciplinary care team approach with the involvement of the individual patient in decision-making process can help optimize prevention and management strategies. This paper aims to demonstrate the growing burden of ageing in real life and illustrates the need to continue primary prevention to address cardiovascular risk factors. It summarizes factors to consider when choosing pharmacological and interventional treatments in the elderly, and the need to consider quality of life and patient priorities when making decisions.